A high-affnity iodinated agonist radioligand for the A2 adenosine receptor has been synthesized to facilitate studies of the A2 adenosine receptor binding subunit. The radioligand '25I-labeled PAPA-APEC (125I-labeled 2-[4-(2-{2- [(4-aminophenyl)methylcarbonylamino]ethylaminocarbonyl}-ethyl)phenyl]ethylamino-5'-N-ethylcarboxamidoadenosine) was synthesized and found to bind to the A2 adenosine receptor in bovine striatal membranes with high affinity (Kd = 1.5 nM) and A2 receptor selectivity. Competitive binding studies reveal the appropriate A2 receptor pharmacologic potency order with
methyl-2-phenylethylladenosine (R-PIA) > (+)-N6-[(S)-
1-methyl-2-phenylethyl]adenosine (S-PIA). Adenylate cyclase assays, in human platelet membranes, demonstrate a dosedependent stimulation of cAMP production. PAPA-APEC (1 pIM) produces a 43% increase in cAMP production, which is essentially the same degree of increase produced by 5'-N-ethylcarboxamidoadenosine (the prototypic A2 receptor agonist). These miS combined with the observed guanine nudeotide-mediated decrease in binding suggest that PAPA-APEC is a full A2 agonist. The A2 receptor binding subunit was identified by photoaffinity-crosslinking studies using 12'Ilabeled PAPA-APEC and the heterobifunctional crosslinking agent N-succinimidyl 6-(4'-azido-2'-nitrophenylamino)hexanoate (SANPAH). After covalent incorporation, a single specifically radiolabeled protein with an apparent molecular mass of 45 kDa was observed on NaDodSO4/PAGE/autoradiography. Incorporation of 1SI-labeled PAPA-APEC into this polypeptide is blocked by agonists and antagonists with the expected potency for A2 receptors (see above) and is decreased in the presence of 10-4 M guanosine 5'-[1,v-imidojtriphosphate. Photoaffinity crosslinking of the Al adenosine receptor binding subunit with 125I-labeled 8-{4-[2-(4-aminophenylacetylamino)ethyllcarbonylmethyloxyphenyl}-1,3-dipropylxanthine (PAPAXAC) (an Al selective photoaffinity probe) in the same tissue reveals a 38-kDa peptide that exhibits the appropriate Al receptor pharmacology. '2I-labeled PAPA-APEC, therefore, has identified the A2 receptor binding subunit as a 45-kDa protein that is unique and distinct from the A1 binding subunit.
Adenylate cyclase-coupled adenosine receptors are divided into two main subtypes (1) . The Al subtype is inhibitory to adenylate cyclase and exhibits the agonist potency order of
The development of a large number of selective high-affinity radioligands and photoaffinity and affinity probes for this receptor subtype has led to the rapid accumulation of information concerning the structure, function, and regulation of the Al adenosine receptor (1) (2) (3) (4) (5) (6) (7) (8) (9) . In contrast, the A2 adenosine receptor is stimulatory to adenylate cyclase and exhibits the distinctly different agonist potency order of NECA > R-PIA > S-PIA. A2 adenosine receptors are distributed in a wide range of tissues including: brain, where they modulate neurotransmitter release; platelets, where they inhibit aggregation and adhesion; and smooth muscle cells, where they may mediate vasodilation (1) . Available radioligands for the A2 receptor have suffered from a number of problems including low affinity, poor specificity, and little selectivity for the A2
receptor. This dearth of useful probes has lead to an almost complete lack of information on the structure, function, and regulation ofthis physiologically important receptor subtype.
We now report on the development of 125I-labeled 2- (Fig. 1 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with Preparation of Bovine Striatal Membranes. The striatal membrane preparation was fashioned after the rat striatal membrane preparation outlined by Bruns et al. (12) . Briefly, the striatum was excised from fresh bovine brain, placed in 20 ml of ice-cold 50 mM Tris-HCl (pH 8.26 at 5°C), minced, and gently disrupted with a motor-drive Teflon pestle. This suspension was centrifuged at 43,000 x g for 10 min, resuspended in 20 ml of Tris buffer, and recentrifuged at 43,000 x g for an additional 10 min. The final pellet was then suspended in sufficient buffer to yield a final protein concentration of 200 mg of wet striatum per ml and stored at -70°C. Frozen membranes were found to remain stable for at least 1 month at this temperature.
Synthesis of '5I-PAPA-APEC. The detailed synthesis of PAPA-APEC will be reported elsewhere. Briefly, the parent compound PAPA-APEC was iodinated by a chloramine-T method (4, 13). The 1"I-PAPA-APEC was completely separated from the starting materials by an isocratic HPLC protocol using a Waters C18 ,Bondapak column and a mobile phase composed of 60%o (vol/vol) methanol and 40%6 (vol/ vol) 20 mM ammonium formate. The purified radioligand was assumed to have a specific activity of 2200 Ci/mmol (1 Ci = 37 GBq).
Ligand Binding Studies. A 1-ml aliquot of frozen striatal membrane was thawed at room temperature and suspended in 9 ml of buffer containing 50 mM Hepes and 10 mM MgCl2 (hereafter referred to as 50/10 buffer), adenosine deaminase (0.2 unit/ml), and 50 nM CPA (final concentration), all adjusted to pH 7.2. Initial studies demonstrated that a low concentration of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) in the incubation buffer dramatically reduced nonspecific binding. Consequently, all the binding and crosslinking studies were performed in the presence of 0.01% CHAPS.
Binding studies were performed in a 250-/l reaction volume consisting of 150 Al (75 ,g of protein) of the above membrane suspension, 50 ,l of diluted ligand, and 50 ,u of either water or competing ligand. The ligand/membrane suspension was incubated at 37°C for 1 hr with continuous shaking. The mixture was then rapidly filtered over glass filters [Schleicher & Schuell, no. 32, treated for 1 hr with 0.3% polyethylenimine (PEI)] and washed three times with 3-ml aliquots of ice-cold 50/10 buffer containing 0.05% CHAPS.
The filters were placed in polypropylene tubes and radioactivity was measured in a Packard y counter.
Adenylate Cyclase Activity. Fresh human platelets membranes were used in adenylate cyclase assays since only the A2 subtype of the adenosine receptor is expressed in this tissue. The platelet membranes were prepared and adenylate cyclase activity was assayed as outlined by Newman et al. Photoaffinity Crosslinking. A 1-ml kaliquot of frozen striatal membranes was thawed and suspended in 9 ml of50/10 buffer (pH 7.2) with adenosine deaminase (0.4 unit/ml). The suspension was incubated at 370C for 15 'min and centrifuged at 43,000 x g for 5 min, and the remaining pellet was suspended in 15 ml of 50/10 buffer containing 0.01% CHAPS and adenosine deaminase (0.2 unit/ml). A volume of 2 ml was used for labeling and consisted of 1.6 ml of the above membrane suspension (-500 jig of protein per/ml), 0.4 ml of water (control) or competing ligand, and a final concentration of 2 nM radioligand. After a 1-hr incubation at 37°C, the membranes were washed once with ice-cold 50/10 buffer containing 0.03% CHAPS, centrifuged at 43,000 x g for 5 min, washed again with 50/10 buffer containing 0.01% CHAPS and, after a final centrifugation, were resuspended in 2 ml of 50/10 buffer containing 0.01% CHAPS. This suspension was then allowed to react with the crosslinking agent SANPAH as described (2, 5) . In brief, 25 ,ul of SANPAH (0.5 mg/ml of Me2SO) was added to the membrane/ligand suspension and allowed to react at room temperature for 5 min. At the end of this time the suspension was poured into a Petri dish (on ice) and UV-irradiated for 4 min at a distance of 1 cm. The photolyzed suspension was then washed once with 50/10 buffer containing 0.05% CHAPS and once with plain 50/10 buffer before being prepared for NaDodSO4/PAGE. NaDodSO4/PAGE. Electrophoresis was performed according to the standard methods outlined by Laemmli (16) Previous studies of various adenosine analogues (20) and the observed effects of guanine nucleotides suggest that PAPA-APEC (which is a substituted adenosine analogue) should be an A2 receptor agonist and stimulate cAMP production. Platelet membranes were employed to assess cAMP generation since adenylate cyclase is more responsive in this tissue than in striatal membranes. Although agonists are known to be less potent at the platelet A2 adenosine receptor than the striatal A2 adenosine receptor (21) (22) (23) , the lack of inhibitory platelet Al receptors more than compensated for the decrease in platelet A2 receptor affinity and led us to use platelet membranes in our cyclase assays. These assays demonstrated the expected A2 receptor agonist-mediated stimulation of cAMP production with an EC50 of =150 nM (n = 3). PAPA-APEC exhibited a 43% increase above basal activity (28.3 pmol per mg of protein per min) at 10-6 M whereas the same concentration of NECA resulted in a 35% increase over basal cAMP activity. The apparent discrepancy between the Kd for binding in brain tissue and the EC50 for cyclase stimulation in platelet membranes can be attributed to tissue differences and is consistent with the differences seen by other investigators studying these same systems (21) .
Although 125I-PAPA-APEC binding clearly exhibits the expected A2 receptor pharmacology, we wished to exclude the possibility that we could be binding to the adenosine (nucleoside) transporter protein. (Fig.  3A) , the magnitude of this decrease in intensity corresponds most closely to the decrease in background activity and not the presence of the competing ligand. This fact is more obvious in Fig. 3B where the 55-kDa band is clearly present in all lanes and supports our belief that the 55-kDa band is a nonspecifically labeled protein.
The possibility that proteolytic degradation of a higher molecular weight polypeptide resulted in the observed specific 45-kDa band led us to prepare fresh striatal membranes in the presence of a combination of proteinase inhibitors [10-4 M phenylmethylsulfonyl fluoride/5 mM EDTA/10-4 M benzamidine/soybean trypsin inhibitor (5 Ag/ml)] shown to inhibit proteolysis in other receptor systems (25) . The full pharmacology of the 1251I-PAPA-APEC-crosslinked receptor in membranes prepared in the presence of these proteinase inhibitors is shown in Fig. 3B and is identical to the results obtained when untreated membranes are labeled. Fig. 3B Fig. 3B suggest that the 45-kDa band is the A2 adenosine receptor binding subunit and that this band is not the result of the proteolytic digestion of a higher molecular weight protein.
The high degree of A2 selectively noted in the saturation binding experiments was also confirmed by photoaffinity crosslinking. An identical distribution and pharmacology of labeled protein was observed in the bovine striatal membranes that were photoaffinity crosslinked in the presence of 50 nM CPA (data not shown). Furthermore, a 38-kDa band (the A1 receptor binding subunit) was never observed in any of the 1251I-PAPA-APEC-labeled lanes, which provides additional evidence of the A2 adenosine receptor selectivity of this ligand.
Although the results are straightforward, it is important to realize that several limitations are inherent in all photoaffinity crosslinking experiments. These limitations have been reviewed elsewhere (26) and include: (i) the labeling of nonreceptor proteins, (ii) the low efficiency of photoincorporation, and (iii) the possibility of "exolabeling" adjacent proteins yielding bands that display the correct pharmacology but provide an erroneous estimate of the apparent molecular mass. Each of these potential problems has been addressed.
The labeling of nonreceptor nonspecific proteins does occur to a small degree in this system and is seen most prominently as a 55-kDa band in Fig. 3 . Fortunately, the degree of nonreceptor labeling and molecular mass of the band does not overlap the regions of interest and, thus, has no effect on our results.
The efficiency of photoincorporation was determined by excising and counting the radioactivity in the appropriate region of the gel that corresponds to the 45-kDa bands in Fig.  3A, lanes 2 
CONCLUSIONS
This study has demonstrated that the agonist radioligand 125I-PAPA-APEC binds specifically, selectively, and with high affinity to a protein that exhibits all the appropriate A2 adenosine receptor pharmacology. Furthermore, this radioligand can be covalently photoincorporated into the A2 receptor binding subunit with the crosslinking agent SANPAH, thus labeling a single specific 45-kDa protein as shown by NaDodSO4/PAGE that also exhibits the appropriate A2 pharmacology. We believe that these photoaffinity crosslinking experiments demonstrate the labeling of the A2 receptor binding subunit and that 125I-PAPA-APEC provides a powerful tool for further studies of the A2 adenosine receptor.
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